, Singapore

Daily Markets Briefing: STI up 0.6%

Index likely to head into a consolidative mode.

OCBC Investment Research said:

The muted reactions on Wall Street overnight are likely to cue the local bourse to a similar start this morning as well.

Following another relatively strong 0.6% climb yesterday, the STI could take a breather and head into a consolidative mode ahead of the weekend break.

For now, we still see the immediate key resistance at the 3485 historical key peak, while the next resistance lies at the 3500 psychological hurdle.

On the downside, the immediate support is still pegged at the 3405 resistance-turned-support, followed by the next base at the recent 3365 trough.

Meanwhile, IG Markets Singapore:

 It will be a busy day in Singapore with earnings from various companies notably UOL Group.

        

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Top News

AI growth stalls as 78% cite weak data infrastructure
Confluent said firms are prioritising data streaming as they move AI projects from pilots into production.
Singapore emerges as key hub in Asia-Pacific’s next medtech wave
The city-state’s regulatory strength helps translate medical innovations into globally validated products.
Healthcare